Acyclovir can reduce the number of days with fever in otherwise healthy children with chickenpox
By www.ncbi.nlm.nih.gov
Chickenpox (varicella) is caused by a virus. It begins with a fever, followed by a rash of red pimples which become itchy sores that form scabs. Chickenpox usually affects children from one to 14 years. In young babies, adults or people with impaired immune system, chickenpox is more severe. Treatments include lotions to relieve itchiness, paracetamol (acetaminophen) for fever and the antiviral drug acyclovir. The review of trials found that acyclovir reduces the number of days of fever from chickenpox in otherwise healthy children, usually without adverse effects. It is not clear whether it improves sores and itching.
Background: Acyclovir has the potential to shorten the course of illness which may result in reduced costs and morbidity associated with chickenpox.
Objectives: To examine the evidence evaluating the efficacy of acyclovir in alleviating symptoms of chickenpox and shortening the duration of illness.
To examine complications of chickenpox and adverse effects associated with acyclovir as reported in the relevant trials.
Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2008, issue 3) which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE (1950 to Septemer Week 3, 2008), and EMBASE (1974 to September 2008). The reference lists of all relevant articles were reviewed.
Selection criteria: Randomized controlled trials that evaluated otherwise healthy children zero to 18 years of age, with chickenpox.
Data collection and analysis: Two review authors independently reviewed the studies for eligibility. Two review authors independently assessed methodological quality of the relevant studies using the Jadad scale and allocation concealment. Differences were resolved by consensus. Data were extracted by one review author using a structured form and checked by a second.
Continuous data were converted to the weighted mean difference (WMD). Weighted mean differences were combined into an overall estimate using random effects. There were too few studies to consider exploring statistical heterogeneity between studies (i.e., differences in reported effects), formally, or to assess for publication bias.
Main results: Three studies were included. Study quality was three (n = 2) and four (n = 1) on the Jadad scale. Acyclovir was associated with a reduction in the number of days with fever (-1.1 days, 95% CI -1.3 to -0.9) and in reducing the maximum number of lesions (-76 lesions, -145 to -8). Results were less supportive with respect to the number of days to no new lesions and the number of days to the relief of itching. There were no clinically important differences between acyclovir and placebo with respect to complications associated with chickenpox or adverse effects associated with the treatment.
Authors' conclusions: Acyclovir appears to be effective in reducing the number of days with fever and the maximum number of lesions among otherwise healthy children with chickenpox. The results were less convincing with respect to the number of days to no new lesions and relief of itchiness. The clinical importance of acyclovir treatment in otherwise healthy children remains uncertain.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0011728/
Saturday, May 16, 2026
Griseofulvin Treatment Approach for Fungal Nail Infection Recovery and Cure Planning
Griseofulvin treatment for fungal nail infection requires understanding how this medication works differently than other antifungal options. This specialized antifungal approach demands patience and specific adherence for success. Griseofulvin works by incorporating into growing nail tissue creating an antifungal barrier that prevents fungal colonization. New nail growing out contains griseofulvin making it hostile to fungal invasion. Infected nail gradually gets replaced by griseofulvin-protected new nail growing from nail root. Treatment duration for fungal nail infection spans months to over a year depending on nail location and growth rate. Toenails require six to twelve months while fingernails typically need three to six months. Complete treatment duration extends until new nail grows completely past infected nail borders. Griseofulvin dosing for fungal nail infection typically involves daily doses taken for extended periods. Your healthcare provider determines specific dosing based on infection severity and body weight. Consistent daily dosing maintains adequate nail griseofulvin concentration throughout treatment. Microsize griseofulvin formulation absorbs better with fatty foods. Taking medication with meals containing fat improves absorption substantially. This absorption pattern differs from other antifungals requiring specific food timing. Ultramicrosize griseofulvin formulations absorb more efficiently than microsize versions. The smaller particle size permits better gastrointestinal absorption with or without food. Healthcare providers sometimes choose ultramicrosize when microsize tolerance remains poor. Learn more about griseofulvin treatment approach during your clinical evaluation for fungal nail infection. Understanding treatment mechanics helps explain why full course completion matters despite slow clinical improvement during early months. Liver function monitoring occasionally occurs during extended griseofulvin therapy. People with liver disease might require dose adjustment. Blood work typically confirms liver function stays within safe parameters during treatment. Medication interactions occur when griseofulvin combines with certain medications including oral contraceptives. Birth control effectiveness sometimes reduces during griseofulvin treatment. Using alternative contraception during and after griseofulvin therapy prevents unintended pregnancy. Warfarin effectiveness sometimes decreases when combined with griseofulvin. Blood clotting monitoring becomes tighter when these medications combine. Your healthcare provider adjusts warfarin dosing based on INR results during griseofulvin therapy. Photosensitivity reactions occasionally occur during griseofulvin therapy. Sun protection including high SPF sunscreen prevents photosensitivity reactions. Most people tolerate griseofulvin well without significant sun sensitivity compared to tetracycline photosensitivity. Gastrointestinal side effects including upset stomach, nausea, and diarrhea occur in some patients during extended griseofulvin therapy. Taking medication with food sometimes reduces these effects. Adjusting dose timing or formulation choice occasionally improves tolerability. Complete nail replacement and clinical cure occur only after new healthy nail grows past infection line completely. Treatment success continues after griseofulvin stops during the months of new nail growth completing replacement. For comprehensive guidance on fungal nail infection management and extended griseofulvin therapy decisions, explore evidence based approaches to onychomycosis treatment. Extended griseofulvin therapy successfully eliminates fungal nail infection through persistent treatment supporting complete nail replacement.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.